Abstract
Several molecular biomarkers have been suggested as predictors of outcome for pediatric ependymomas but deserve further validation in independent case series. We analyzed intracranial ependymomas belonging to a series of 60 patients prospectively treated according to the protocol sponsored by the Italian Association of Pediatric Hematology-Oncology. We used a tissue microarray to analyze nucleolin (NCL), cyclin-dependent kinase inhibitor 2A (CDKN2A), tumor protein 53 (TP53), and epidermal growth factor receptor (EGFR) by immunohistochemistry and by 1q gain by fluorescent in situ hybridization. The mRNA expression levels of EGFR, human telomerase reverse-transcriptase (HTERT), and Prominin 1 (PROM 1)/CD133 were evaluated by quantitative real-time PCR from cases with fresh-frozen tumor material available. Univariate and multivariate analyses of updated clinical data confirmed the prognostic significance of surgery (P
Original language | English |
---|---|
Pages (from-to) | 1346-1356 |
Number of pages | 11 |
Journal | Neuro-Oncology |
Volume | 14 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2012 |
Keywords
- biomarker
- EGFR
- ependymoma
- HTERT
- nucleolin
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Clinical Neurology